369-43-7

Usage

Uses

Used in Pharmaceutical Industry:
2-Amino-4'-fluoroacetophenone is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of new drugs and medications. Its unique structure allows for the creation of compounds with specific therapeutic properties.
Used in Organic Compounds Synthesis:
As an intermediate, 2-Amino-4'-fluoroacetophenone is utilized in the synthesis of organic compounds, where its structural features can be leveraged to produce a range of chemical products with diverse applications.
Used in Fine Chemicals Production:
2-Amino-4'-fluoroacetophenone serves as a building block in the production of fine chemicals, which are high-purity chemicals used in various industries, including pharmaceuticals, agriculture, and materials science.
Used in Agrochemicals Development:
2-Amino-4'-fluoroacetophenone is also used in the development of agrochemicals, contributing to the creation of products that enhance crop protection and agricultural productivity.

Upstream product

• 403-29-2 2-bromo-4'-fluoroacetophenone 

Downstream Products

• 113485-27-1 N-(4'-fluorophenacyl)isonicotinamide 
• 877319-43-2 tert-butyl (2-(4-fluorophenyl)-2-oxoethyl)carbamate 

Relevant academic research and scientific papers

Design, synthesis, and cytotoxic activity of novel 2H-imidazo[1,2-c]pyrazolo[3,4-e]pyrimidine derivatives

In this study, a series of novel 2H-imidazo [1, 2-c] pyrazolo [3, 4-e] pyrimidine derivatives were designed, synthesized, and evaluated for their cytotoxic activities. The in vitro cell growth inhibition assay of the target compounds indicated their selectivity in inhibiting the proliferation of blood tumor cells (K562, U937) and solid tumor cells (HCT116, HT-29). Compound 9b exhibited the highest antiproliferative activities against K562 (IC50 = 5.597 μM) and U937 (IC50 = 3.512 μM). Based on the flow cytometry assays, compound 9b caused obvious induction of cell apoptosis and cell arrest at the S phase. Furthermore, western blot analysis revealed that compound 9b upregulated the expression of Bax, downregulated the levels of Bcl-2, and further activated caspase-3 in K562 cells. Therefore, compound 9b may be a potential anticancer agent that deserves further investigation.

Pyrazole-pyrimido imidazole compound as well as preparation method and application thereof

The invention relates to a pyrazole-pyrimido imidazole compound as well as a preparation method and application thereof, and belongs to the field of medicinal chemistry and pharmacotherapeutics. The invention provides application of the compound shown in the formula I or the pharmaceutically acceptable salt thereof in preparation of drugs for treating tumor-related diseases.

Novel morpholine scaffolds as selective dopamine (DA) D3 receptor antagonists

A new series of morpholine derivatives has been identified as selective DA D3 receptor antagonists; their in vitro profile and pharmacokinetic data are provided.

Hit-to-lead evaluation of a novel class of sphingosine 1-phosphate lyase inhibitors

Inhibition of sphingosine-1-phosphate lyase has recently been proposed as a potential treatment option for inflammatory disorders such as multiple sclerosis, rheumatoid arthritis, and inflammatory bowel disease. In this report we describe our hit-to-lead evaluation of the isoxazolecarboxamide 6, a high-throughput screening hit (in vitro IC50 = 1.0 μM, cell IC50 = 1.8 μM), as a novel S1P lyase inhibitor. We were able to establish basic structure-activity relationships around 6 and succeeded in obtaining X-ray structural information which enabled structure-based design. With the discovery of 28, enzyme activity was quickly improved to IC50 = 120 nM and cell potency to IC50 = 230 nM. The main liability in the established isoxazolecarboxamide hit series was determined to be metabolic stability. In particular we identified that future lead-optimization efforts to overcome this problem should focus on blocking the N-dealkylation on the secondary amine.

A QUINOLINE AMIDE DERIVATIVE AS AGENT AGAINST DISORDERS OF THE CNS

A compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, is provided (Formula I) as is a process for its preparation and methods for its use in therapy, particularly in treating CNS or CNS-mediated disorders.